- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Access and Rational Use > Pricing
- Mots-clés > access to essential medicines and technologies for NCDs
- Mots-clés > access to medicines
- Mots-clés > availability
- Mots-clés > chronic diseases
- Mots-clés > NCDs - cost-effective intervention strategies
- Mots-clés > noncommunicable disease
- Mots-clés > pharmaceutical industry - research-based
- Mots-clés > pharmaceutical industry partnership
- Mots-clés > policy
- Mots-clés > strategies
(2011; 86 pages)
This document was published with copyright permission from RAND.
Non-communicable diseases (NCDs) now account for the majority of global morbidity and mortality and are increasingly affecting developing countries whose under-resourced health care systems also have to handle a high burden of infectious disease. To counter the global devastation caused by NCDs, the United Nations General Assembly decided to "set a new global agenda" and is convening a high-level meeting on NCDs in September 2011. In connection with this meeting, the authors of this paper took a first step toward developing a policy research agenda for improving access to NCD medicines in developing countries, a step that the research-based pharmaceutical industry, in particular, can carry forward as part of broader global efforts to combat NCD. The authors provide a framework for understanding the obstacles to access for NCD medicines, review specific issues to be confronted within each obstacle in the developing world, identify promising ideas for improving access to NCD medicines, and point to several highly promising areas for the research-based pharmaceutical industry to focus on as it develops its NCD policy research program in close collaboration with other key stakeholders.